Emily Rafferty - Evolent Health Executive Success
| EVH Stock | USD 2.99 -0.07 -2.29% |
Executive
Emily Rafferty is Executive Success of Evolent Health
| Age | 42 |
| Address | 1812 N. Moore Street, Arlington, VA, United States, 22209 |
| Phone | 571 389 6000 |
| Web | https://www.evolent.com |
Evolent Health Management Efficiency
The company has Return on Asset of -0.13 % which means that it is not converting its asset base into profit. This is a lagging result relative to sector standards. In the same way, it shows a return on shareholders' equity (ROE) of -66.54 %, which means that it produced no profit with money invested by stockholders.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kevin OHara | HealthStream | 54 | |
| David Hammer | Myriad Genetics | N/A | |
| Jennifer LoPresto | HealthStream | 53 | |
| Andrew Schwendenman | Replimune Group | 50 | |
| Julie Purinton | AMN Healthcare Services | N/A | |
| Deepshikha Bhandari | Personalis | N/A | |
| Kari Jeschke | Replimune Group | N/A | |
| Justin Hunter | Myriad Genetics | N/A | |
| MBA FACHE | Nutex Health | 49 | |
| Nina Aragam | Replimune Group | N/A | |
| Ashish Kheterpal | Personalis | N/A | |
| Mark Milliner | Nutex Health | N/A | |
| Stephen JD | Personalis | 53 | |
| Patrick Burke | Myriad Genetics | N/A | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Paul Bullock | Replimune Group | N/A | |
| MBA MD | Replimune Group | 58 | |
| Jeff Decker | AMN Healthcare Services | N/A | |
| Scott Leffler | Myriad Genetics | 50 | |
| Tomya Watt | AMN Healthcare Services | N/A | |
| Ben Wheeler | Myriad Genetics | N/A | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.0013 |
Evolent Health Leadership Team
Elected by the shareholders, the Evolent Health's board of directors comprises two types of representatives: Evolent Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolent. The board's role is to monitor Evolent Health's management team and ensure that shareholders' interests are well served. Evolent Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolent Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General Officer | ||
| Geoff McHugh, Chief Officer | ||
| Thomas Peterson, Chief Operating Officer | ||
| Katie Cook, Chief Officer | ||
| Elizabeth Cato, Utilization Director | ||
| Robert Cruz, Chief Officer | ||
| Dan McCarthy, CEO President | ||
| John MD, Chief Officer | ||
| Nicholas McGrane, Executive Vice President of Corporate Performance | ||
| Bridget Duffy, Independent Director | ||
| Tunde Sotunde, Independent Director | ||
| Andrew MD, Chief Advisor | ||
| MAAA FSA, Chief Officer | ||
| Emily Rafferty, Executive Success | ||
| Bruce Felt, Independent Director | ||
| John Johnson, Chief Financial Officer | ||
| M Duffy, Independent Director | ||
| John Way, Chief Suite | ||
| Craig Barbarosh, Independent Director | ||
| Steve Tutewohl, Chief Operating Officer | ||
| Cheryl Scott, Lead Independent Director | ||
| Jordan Silvergleid, Chief Officer | ||
| Richard Cochran, Market President | ||
| Seth Blackley, Chief Executive Officer, Co-Founder, Director | ||
| Frank Williams, Co-Founder, CEO, Director and Chairman of Nominating and Governance Committee | ||
| Jonathan Weinberg, General Counsel | ||
| David Farner, Director | ||
| Aammaad Shams, Interim Principal Accounting Officer and Corporate Controller | ||
| Jessica Somers, Sr Devel | ||
| Seth Frank, Vice Relations | ||
| Mark Mannion, Senior Finance | ||
| Scott Pritchard, President Suite | ||
| Mario Ramos, Chief Officer | ||
| Peter Grua, Independent Director | ||
| Heather Orth, Market President | ||
| David Lim, Chief Officer | ||
| Diane Holder, Director | ||
| Michael DAmato, Independent Director | ||
| Kali Beyah, Chief Officer | ||
| Jessica White, Chief Officer | ||
| Kim Keck, Independent Director | ||
| MPH MD, Chief Officer |
Evolent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolent Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.0013 | ||||
| Profit Margin | -0.28 % | ||||
| Operating Margin | -0.02 % | ||||
| Current Valuation | 1.17 B | ||||
| Shares Outstanding | 111.64 M | ||||
| Shares Owned By Insiders | 1.64 % | ||||
| Shares Owned By Institutions | 98.36 % | ||||
| Number Of Shares Shorted | 18.33 M | ||||
| Price To Earning | -13.88 X |
Currently Active Assets on Macroaxis
More Resources for Evolent Stock Analysis
A structured review of Evolent Health often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Key reports that frame Evolent Health Stock are listed below:Evolent Health has a market cap of 333.8 M, operating margin of -2.06%, ROE of -66.54%. Investing Opportunities can help frame allocation decisions. The allocation includes a position in Evolent Health in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. Get started with Evolent Stock investing by reading our How to Invest in Evolent Stock guide.Analysis related to Evolent Health should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Earnings Share -5.07 | Revenue Per Share | Quarterly Revenue Growth -0.28 | Return On Assets | Return On Equity |
Market capitalization and book value offer complementary views of Evolent Health — the first driven by investor sentiment, the second by accounting standards. Evolent Health's market capitalization is 333.8 M. A P/B ratio of 0.8 suggests Evolent Health trades near or below book value. Enterprise value stands at 1.17 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Value and price for Evolent Health are related but not identical, and they can diverge across cycles. For Evolent Health, key inputs include a P/B ratio of 0.8, a profit margin of -28.49%, ROE of -66.54%, and revenue of 1.88 B. Trading price represents the transaction level agreed by market participants.